CIK 0001797768
KNTE Kinnate Biopharma Inc.
Insider trading from SEC Form 4. Last filing Apr 5, 2024.
In brief
Kinnate Biopharma Inc. (KNTE) has 51 SEC Form 4 filings on file from 14 insiders, the latest filed on Apr 5, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
6 open-market trades have been scored at KNTE. The newest: Foresite Capital Management IV, LLC (10% owner) bought $5.0M of stock on May 8, 2023, filed May 10, 2023, scored 57 (moderate). 4 insiders bought within 14 days of each other around May 8, 2023.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Signals
Open-market buys and sells at Kinnate Biopharma Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Foresite Capital Management IV, LLC owner buy | $5.0M 1,780,000 shares | +90% | - | |
| 75Notable | James B. Tananbaum director, owner buy | $5.0M 1,780,000 shares | +90% | - | |
| 65Notable | Carl L Gordon director, owner buy | $4.1M 1,460,932 shares | +184% | - | |
| 65Notable | Orbimed Advisors LLC director, owner buy | $4.1M 1,460,932 shares | +184% | - | |
| 60Notable | Carl L Gordon director, owner buy | $3.7M 1,405,168 shares | +255% | - | |
| 60Notable | Orbimed Advisors LLC director, owner buy | $3.7M 1,405,168 shares | +255% | - |
Transactions
The newest 50 of 127 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 3, 2024 | Foresite Capital Management IV, LLC owner | DDisposition to issuer Common Stockindirect: See Footnote | -9,671,643 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Helen Sabzevari director | DDisposition to issuer Stock Option (right to buy)derivative | -40,501 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Epperly Melissa B director | DDisposition to issuer Stock Option (right to buy)derivative | -60,751 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | James B. Tananbaum director, owner | DDisposition to issuer Common Stockindirect: By Fund | -9,671,643 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Keith T. Flaherty director | DDisposition to issuer Common Stock | -66,377 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Neha Krishnamohan CHIEF FINANCIAL OFFICER | DDisposition to issuer Common Stock | -64,087 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Orbimed Advisors LLC director, owner | DDisposition to issuer Common Stockindirect: See footnotes | -1,368,339 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Michael E Rome director | DDisposition to issuer Stock Option (right to buy)derivative | -40,501 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Carl L Gordon director, owner | DDisposition to issuer Common Stockindirect: See footnotes | -1,368,339 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Mark A Meltz COO GENERAL COUNSEL SECRETARY | DDisposition to issuer Common Stock | -27,578 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Alsup Laurie Smaldone director | DDisposition to issuer Stock Option (right to buy)derivative | -60,751 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Dean J Mitchell director | DDisposition to issuer Stock Option (right to buy)derivative | -121,503 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Nima Farzan CHIEF EXECUTIVE OFFICER | DDisposition to issuer Common Stock | -2,186 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Jill DeSimone director | DDisposition to issuer Stock Option (right to buy)derivative | -50,000 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | James B. Tananbaum director, owner | DDisposition to issuer Common Stockindirect: By Fund | -3,525,957 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Mark A Meltz COO GENERAL COUNSEL SECRETARY | DDisposition to issuer Stock Option (right to buy)derivative | -384,508 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Foresite Capital Management IV, LLC owner | DDisposition to issuer Common Stockindirect: See Footnote | -3,525,957 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Michael E Rome director | DDisposition to issuer Stock Option (right to buy)derivative | -20,250 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Carl L Gordon director, owner | DDisposition to issuer Common Stockindirect: See footnotes | -4,738,453 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Alsup Laurie Smaldone director | DDisposition to issuer Stock Option (right to buy)derivative | -20,250 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Dean J Mitchell director | DDisposition to issuer Stock Option (right to buy)derivative | -20,250 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Neha Krishnamohan CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -270,000 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Keith T. Flaherty director | DDisposition to issuer Stock Option (right to buy)derivative | -32,064 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Helen Sabzevari director | DDisposition to issuer Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Nima Farzan CHIEF EXECUTIVE OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -1,281,642 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Epperly Melissa B director | DDisposition to issuer Stock Option (right to buy)derivative | -20,250 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Orbimed Advisors LLC director, owner | DDisposition to issuer Common Stockindirect: See footnotes | -4,738,453 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Orbimed Advisors LLC director, owner | DDisposition to issuer Common Stockindirect: See footnotes | -1,368,338 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | James B. Tananbaum director, owner | DDisposition to issuer Common Stockindirect: By Fund | -520,711 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Nima Farzan CHIEF EXECUTIVE OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -437,413 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Mark A Meltz COO GENERAL COUNSEL SECRETARY | DDisposition to issuer Stock Option (right to buy)derivative | -121,503 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Epperly Melissa B director | DDisposition to issuer Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Neha Krishnamohan CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -185,000 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Foresite Capital Management IV, LLC owner | DDisposition to issuer Common Stockindirect: See Footnote | -520,711 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Helen Sabzevari director | DDisposition to issuer Stock Option (right to buy)derivative | -20,250 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Alsup Laurie Smaldone director | DDisposition to issuer Stock Option (right to buy)derivative | -20,250 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Carl L Gordon director, owner | DDisposition to issuer Common Stockindirect: See footnotes | -1,368,338 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Dean J Mitchell director | DDisposition to issuer Stock Option (right to buy)derivative | -20,250 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Keith T. Flaherty director | DDisposition to issuer Stock Option (right to buy)derivative | -56,112 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Dean J Mitchell director | DDisposition to issuer Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Orbimed Advisors LLC director, owner | DDisposition to issuer Common Stockindirect: See footnotes | -84,599 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Nima Farzan CHIEF EXECUTIVE OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -275,000 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Mark A Meltz COO GENERAL COUNSEL SECRETARY | DDisposition to issuer Stock Option (right to buy)derivative | -100,000 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Epperly Melissa B director | DDisposition to issuer Stock Option (right to buy)derivative | -20,250 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | James B. Tananbaum director, owner | DDisposition to issuer Stock Option (right to buy)derivative | -40,501 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Neha Krishnamohan CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -215,000 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Alsup Laurie Smaldone director | DDisposition to issuer Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Carl L Gordon director, owner | DDisposition to issuer Common Stockindirect: See footnotes | -84,599 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Keith T. Flaherty director | DDisposition to issuer Stock Option (right to buy)derivative | -11,391 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | Keith T. Flaherty director | DDisposition to issuer Stock Option (right to buy)derivative | -20,250 | - | - | 0 | Apr 5, 2024 |
50 of 127 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Jill DeSimonedirector
- Epperly Melissa Bdirector, cfo, officer
- Nima FarzanChief Executive Officer
- Keith T. Flahertydirector
- Foresite Capital Management IV, LLCowner
- Carl L Gordondirector, owner
- Neha KrishnamohanChief Financial Officer
- Dean J Mitchelldirector
- Mark A MeltzCOO General Counsel Secretary
- Orbimed Advisors LLCdirector, owner
- Michael E Romedirector
- Helen Sabzevariceo, president, officer, director
- Alsup Laurie Smaldonedirector
- James B. Tananbaumdirector, owner, ceo, president, officer
Questions about KNTE
Answered from the filings on this page, as of the latest one.
Are insiders buying KNTE?
No. In the last 90 days no insider at Kinnate Biopharma Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade KNTE on the open market?
Foresite Capital Management IV, LLC (10% owner) bought $5.0M of KNTE on May 8, 2023 and filed the Form 4 on May 10, 2023. InsiderTell scored 57 (moderate), with 4 insiders on the same side within 14 days.
How many insiders file Form 4 at Kinnate Biopharma Inc.?
14 people have filed a Form 4 at Kinnate Biopharma Inc., among them Jill DeSimone (director), Epperly Melissa B (director and CFO), Nima Farzan (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.